IL5 and hypereosinophilic syndrome: As with EGPA, testing IL-5/IL-5R therapies in HES has helped in two ways: first, by proving that reducing eosinophil counts can be an effective strategy for this population of patients in desperate need of new therapies, and second, by providing proof of concept that eosinophilic immune dysfunction is indeed an important part of HES.